LLY

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2001 for Eli Lilly & Co, a pharmaceutical company headquartered in Indianapolis, Indiana. The company operates primarily in one significant business segment: pharmaceutical products for human use, with a non-material animal health division. As of April 30, 2001, there were 1,123,882,663 shares of common stock outstanding.

Key Financial Metrics

Balance Sheet Highlights (March 31, 2001): Total assets were $14,752.4 million. Current liabilities totaled $4,469.2 million, and long-term debt was $2,656.5 million. Shareholders' equity stood at $6,593.6 million.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 14% to $2.81 billion. Adjusting for year-2000 wholesaler buying impacts, worldwide sales grew 10%. Growth was driven by Zyprexa (+39%), Evista (+48%), Gemzar (+28%), and diabetes care products (+19%). This was partially offset by a 14% decline in anti-infectives sales.
• Profitability: Reported net income decreased 5% to $806.8 million. However, excluding unusual items in 2000 (a $214.4 million gain on the sale of Kinetra LLC and $91 million in Y2K-related sales), adjusted net income increased 17%.
• Expenses: Operating expenses (R&D and Marketing/Admin) increased 12% due to pipeline investment and sales force expansion. R&D spending rose to $515.5 million.
• Cash Flow: Operating cash flow decreased to $527.6 million from $610.2 million. Investing activities used $1,066.6 million, primarily due to a $909.0 million purchase of investments.

Guidance, Outlook, and Risks

Management Commentary and Outlook

Management expects full-year 2001 earnings per share (excluding unusual items) to be in the range of $2.75 to $2.85, assuming generic fluoxetine enters the U.S. market in August 2001. For the second quarter of 2001, EPS is expected to be between $0.73 and $0.75.

The company is executing a $3 billion share repurchase program, having repurchased approximately 4.0 million shares in Q1 2001 for $316.3 million.

Risks and Contingencies

• Prozac Patent Litigation: A federal appeals court upheld the 2001 compound patent but ruled the 2003 method-of-use patent invalid. The company expects a "very substantial decline" in U.S. Prozac sales following generic entry (as soon as August 2001). Prozac accounted for approximately 19% of consolidated worldwide sales in Q1 2001.
• Zyprexa Litigation: Zenith Goldline Pharmaceuticals has challenged Zyprexa patents. An unfavorable outcome could materially impact results.
• Regulatory Issues: The company received an FDA warning letter regarding manufacturing quality (cGMP) at one plant and is implementing company-wide improvements. Additionally, the FTC is investigating industry practices regarding generic competition delays.
• Environmental and Liability: The company has accrued approximately $137.6 million for environmental and product liability matters (primarily DES and Prozac), with estimated insurance recoverables of $73.3 million.

Investor Verification Checklist

• Verify the timeline and market impact of generic fluoxetine (Prozac) entry in the U.S., specifically regarding the August 2001 exclusivity expiration.
• Monitor the status of the rehearing petition regarding the Prozac 2003 patent invalidity ruling.
• Track the progress of FDA inspections for the company's manufacturing sites and its contract manufacturers (Lonza and Catalytica) to ensure no production interruptions.
• Review the outcome of the Zyprexa patent litigation against Zenith Goldline Pharmaceuticals.
• Assess the sustainability of sales growth in key products (Zyprexa, Evista, Gemzar) to offset the anticipated decline in Prozac revenues.